(Bcl-2) complexes using a cell-permeable peptide (stabilized TAT-fused IP3R-derived peptide (TAT-IDPS)) that selectively targets the BH4 domain of Bcl-2 but not that of B-cell lymphoma 2-extra large (Bcl-Xl) potentiated pro-apoptotic Ca2 þ signaling in chronic lymphocytic leukemia ...
A randomized, two-sequence, assessor-blinded study involving two separate experiments was undertaken to measure the potency and persistence of acute pain control over 24 h resulting from a single oral dose of either firocoxib (Previcox) or grapiprant (Galliprant) in an acute arthritis model. ...
While Th17 cells can protect against colonization by pathogenic organisms, they also have the potential to become pathogenic and promote autoimmune and inflammatory diseases. Mechanisms that control their pathogenic potential remain poorly understood. Here we show that Ndfip1, a co-activator of the E3...
(IP3R)/B-cell lymphoma 2 (Bcl-2) complexes using a cell-permeable peptide (stabilized TAT-fused IP3R-derived peptide (TAT-IDPS)) that selectively targets the BH4 domain of Bcl-2 but not that of B-cell lymphoma 2-extra large (Bcl-Xl) potentiated pro-apoptotic Ca2+ signaling in ...
developed a method to efficiently incorporate the UAA difluorotyrosine (F2Y) into proteins of interest, enabling us to study how different receptor phospho-barcodes localized in the receptor C-tail regulate distinct functionally selective arrestin conformations12,13. Despite this significant progress, ...
The original article [1] contains two mistaken instances of the molecule 'fipronil' in the results. These should instead have stated 'firocoxib'.doi:10.1186/S12917-019-2052-0Andrea García de Salazar AlcaláLucile GiodaAlia DehmanFrederic Beugnet...